Talks for a global settlement have begun between pharmaceutical giant AbbVie and plaintiffs in the thousands of testosterone lawsuits related to the company’s flagship testosterone replacement therapy medication, AndroGel. If a settlement agreement is reached, it would bring an end to the multidistrict litigation (MDL) that has been in progress since 2014.

Read the source article at Personal Injury Lawyers.